In Year 2 (June 1 2021-March 31 2022), we aim to leverage our established infrastructure to create a national vaccine evaluation platform in partnership with provincial Public Health Partners.
We will evaluate Vaccine Effectiveness (VE) and duration of protection in priority populations who commonly receive care in EDs for symptomatic and severe COVID-19, and were inadequately evaluated in or excluded from phase 3 VE trials.
Our specific objectives are to evaluate:
The effectiveness of COVID-19 vaccines for preventing severe COVID-19 in priority groups, including in racialized and Indigenous communities, individuals of lower socioeconomic status (SES), those with active comorbidity (e.g., active cancer), at the extremes of ages, in pregnant and breastfeeding women, and in otherwise marginalized groups (e.g., homeless);
The effectiveness of COVID-19 vaccines in preventing severe disease, hospitalization and mortality, as delivered in the real-world, including single doses of vaccines authorized as two-dose series, delayed boosters, and receipt of vaccines from different manufacturers; and
The duration of vaccine protection from symptomatic COVID-19 in the general population and in specific groups (e.g., elderly with immune senescence), by vaccine type, for single doses of vaccines authorized as two-dose series, and in individuals receiving a delayed booster.